Valuation: Structure Therapeutics Inc.

Market Cap 3.27B 2.86B 2.64B 2.43B 4.58B 315B 4.69B 31.53B 12.4B 154B 12.29B 12.02B 531B P/E 2026 *
-32.2x
P/E 2027 * -22.1x
Enterprise Value 2.2B 1.92B 1.77B 1.63B 3.08B 212B 3.15B 21.19B 8.34B 104B 8.26B 8.08B 357B EV / Sales 2026 *
57.2x
EV / Sales 2027 * 60,761x
Free-Float
76.06%
Yield 2026 *
-
Yield 2027 * -
1 day+5.32%
1 week-9.15%
Current month-9.67%
1 month+7.73%
3 months-4.47%
6 months-46.74%
Current year-30.29%
1 week 44.8
Extreme 44.8001
53
1 month 43.98
Extreme 43.985
57.07
Current year 35.78
Extreme 35.78
94.77
1 year 15.8
Extreme 15.8
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Tech/Sci/R&D Officer 52 18/09/2024
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap.
7/14/26 A Fiscal year

Chief Technology Officer

86,658 0.0620%
6/25/26 A Fiscal year

Chief Technology Officer

86,658 0.0620%
6/17/26 A Free

Director

39,453 0.0282%
Change 5-day change 1-year change 3-year change Capi.($)
+5.32%-9.15%+148.23%+37.53% 3.27B
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-6.31%+3.98%+423.29% 23.29B
-0.09%-0.01%-17.62%-14.67% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
Average -1.94%-2.78%+54.68%+176.19% 24.38B
Weighted average by Cap. -2.79%-2.39%+45.12%+155.43%

Financials

2026 *2027 *
Net sales 38.46M 33.61M 31.02M 28.59M 53.88M 3.7B 55.08M 371M 146M 1.81B 144M 141M 6.24B 41.67K 36.42K 33.6K 30.97K 58.38K 4.01M 59.68K 402K 158K 1.97M 156K 153K 6.77M
Net income -288M -251M -232M -214M -403M -27.69B -412M -2.77B -1.09B -13.56B -1.08B -1.06B -46.69B -423M -370M -341M -315M -593M -40.75B -606M -4.08B -1.6B -19.96B -1.59B -1.55B -68.7B
Net Debt -1.07B -938M -865M -798M -1.5B -103B -1.54B -10.34B -4.07B -50.6B -4.03B -3.94B -174B -740M -646M -596M -550M -1.04B -71.23B -1.06B -7.13B -2.8B -34.89B -2.78B -2.72B -120B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
233
Date Price Change Volume
17/07/26 $48.48 +5.32% 915,184
16/07/26 $46.03 -7.23% 654,227
15/07/26 $49.62 -1.92% 684,482
14/07/26 $50.59 -2.03% 565,872
13/07/26 $51.64 -3.22% 490,987
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
46.03USD
Average target price
104.59USD
Spread / Average Target
+127.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock